Search for content and authors
 

Hexenoses in design of glycoconjugates – from chemistry to function

Piotr Krzeczyński 1Grzegorz Grynkiewicz 1Wiesław Szeja 2

1. Pharmaceutical Research Institute (IF), Rydygiera 8, Warszawa 01-793, Poland
2. Silesian University of Technology, Department of Organic Chem., Bioorganic Chem. and Biotechnol., Krzywoustego 4, Gliwice 44-100, Poland

Abstract

Isoflavones have received a great deal of attention over the last decades as possible drug leads with demonstrated activity against multiple targets. However, their poor bioavailability and quick metabolism result in low efficacy and call for well designed synthetic modifications before potential medicinal application. Our lasting interest in unsaturated pyranosides prompted syntheses of various isoflavone glycosides, exemplified by genistein derivative IF021, containing hex–2–enopyranose moiety.

Although IF021 was designed as genistein pro-drug, and similar effects in cell tests were predicted, it turned out that it has distinctly different biological activity profile than the parent isoflavone [1; 2] with unexpected cytotoxicity related to interference with the mitotic spindle dynamics. Despite our efforts, laboratory synthesis of IF021 proved poorly stereoselective, offering no hope for elaboration of efficient manufacturing process. Considering hex-2-enopyranosides as the new type of saccharide scaffold which may be useful in medicinal chemistry, we have decided to examine synthetic methods of its linkage to selected polyphenolic substrates by several strategies involving Ferrier rearrangement and transition metals promoted glycosylations. Apart from straight isoflavone – glycon bonding, variety of linkers were tried for obtaining

O-linked or C-linked glycoconjugates. Generally, all types of unsaturated isoflavone glycoconjugates exhibited specific influence on cell cycle, which warrants more specific pharmacological research.

References:

[1] K. Polkowski, J. Popiołkiewicz, P. Krzeczyński, J. Ramza, W. Pucko, O. Zegrocka-Stendel, J. Boryski, J.S. Skierski, A.P. Mazurek, G. Grynkiewicz, Cytostatic and cytotoxic activity of synthetic genistein glycosides against human cancer cell lines, Cancer Lett., 203, 59 (2004).

[2] A. Rusin, J. Zawisza-Puchałka, K. Kujawa, A. Gogler-Pigłowska, J. Wietrzyk, M. Świtalska, M. Głowala-Kosińska, A. Gruca, W. Szeja, Z. Krawczyk, G. Grynkiewicz, Synthetic conjugates of genistein affecting proliferation and mitosis of cancer cells, Bioorg. Med. Chem., 19, 295-305 (2011).

Acknowledgement:
This work was supported by the Statutory Fund of Pharmaceutical Research Institute.

 

Legal notice
  • Legal notice:
 

Related papers

Presentation: Oral at IX Multidyscyplinarna Konferencja Nauki o Leku, by Piotr Krzeczyński
See On-line Journal of IX Multidyscyplinarna Konferencja Nauki o Leku

Submitted: 2014-03-18 12:03
Revised:   2014-05-02 12:25